Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
major depressive disorder
Biotech
Biohaven flunks depression trial, adding to CNS release concerns
As the biopharma wound down for the holidays, the company reported the failure of a midphase study of BHV-7000 for the treatment of MDD.
Nick Paul Taylor
Jan 2, 2026 4:48am
Neurocrine-Takeda psychiatry pact suffers another phase 2 fail
Nov 11, 2025 6:25am
AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic program
Aug 25, 2025 9:42am
HMNC recalibrates precision depression push after phase 2b miss
Aug 5, 2025 10:38am
AbbVie in talks over $1B Gilgamesh buyout: report
Jul 31, 2025 7:48am
Relmada dumps depression asset after slew of phase 3 failures
Jul 11, 2025 12:12pm
